 |
|
Genetic Associations With Age-Related Macular Degeneration
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: In their study of the Age-Related Eye Disease Study (AREDS) participants,1 Dr Seddon and colleagues investigated whether genetic variants were associated with progression of age-related macular degeneration. In the article, they did not present the main results stratified by treatment assignment. Results for the antioxidants-plus-zinc group and the placebo group would have been a useful addition to Table 6 in the article. The authors did note that genotype and treatment had no significant interaction, but interaction tests may have very low statistical power.
Providing these specific results would also help interpret the corrected abstract conclusion: "Presence of these polymorphisms plus smoking and body mass index of 25 or higher, controlling for AREDS vitamin-mineral treatment, identifies patients who are highly susceptible to developing advanced stages of this visually disabling disease."1 The treatment used in AREDS appears to be one of the few options to help manage this public . . . [Full Text of this Article]
Javier Damián, MD, MPH
jdamian@isciii.es
National Centre for Epidemiology
Carlos III Health Institute
Madrid, Spain
RELATED LETTER
Genetic Associations With Age-Related Macular Degeneration—Reply
Johanna M. Seddon, Peter J. Francis, Michael L. Klein, and Bernard Rosner
JAMA. 2007;298(14):1637.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Association of CFH Y402H and LOC387715 A69S With Progression of Age-Related Macular Degeneration
Johanna M. Seddon, Peter J. Francis, Sarah George, Dennis W. Schultz, Bernard Rosner, and Michael L. Klein
JAMA. 2007;297(16):1793-1800.
ABSTRACT
| FULL TEXT
|
